PBM PSYENCE BIOMEDICAL LTD. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.95

Period return

-1.19 (-28.81%)

Volume

41.5K

2026-07-24O $2.94 H $3 L $2.8 C $2.95MA5 $3MA20 $3MA60 $3.88MA120 $3.68

6M · 125 barsYahoo Finance · USD2026-01-26 → 2026-07-24

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

No events to show.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Sector: Healthcare
Industry: Biotechnology
HQ: Toronto, ON, Canada
Fiscal year end: —
Employees: 12
IPO date: —

PSYENCE BIOMEDICAL LTD.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats